Variant · Deletion Cna
CIC Loss
CI-VAR-00002484Explore in graph →CIViC 1876
Curated evidence
Evidence by cancer (9 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 28178529
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Malignant Colon Neoplasm2 | ||||||||
| CIC Loss | Trametinib | Predictive | D | Supports Resistance | 3 | submitted | EID5111CIC knockout conferred resistance to trametinib in KRAS G13D (HCT116) and BRAF V600E (HT29) colon cancer cell lines. PMID 28178529 · Wang et al., 2017 · Open in CIViC | civic |
| CIC Loss | Vemurafenib | Predictive | D | Supports Resistance | 3 | submitted | EID5112CIC knockout conferred resistance to vemurafenib in BRAF V600E (HT29) colon cancer cells. PMID 28178529 · Wang et al., 2017 · Open in CIViC | civic |
| Malignant Lung Neoplasm3 | ||||||||
| CIC Loss | ||||||||
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available